Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and raises the price target from $7 to $13.
May 31, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Summit Therapeutics and raises the price target from $7 to $13.
The raised price target from $7 to $13 by a reputable analyst at Citigroup is a strong positive signal for investors, likely leading to increased buying interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100